NCT00002392已完成不适用
A Study to Investigate the Potential of Thalidomide Treatment to Enhance Immune Responses in HIV-Infected Individuals Who Are Receiving Highly Active Antiretroviral Therapy.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
研究概览
简要总结
To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and parameters of specific, anti-HIV cellular immunity.
详细描述
Patients receive oral thalidomide in a blinded, placebo-controlled study. [AS PER AMENDMENT 11/25/98: This is a double-blind, placebo-controlled trial in which thalidomide or placebo is administered for 21 days. After the first week of therapy, patients receive immunizations with keyhole limpet hemocyanin and polyvalent pneumococcal vaccine. Study therapy is stopped for 2 weeks after the immunizations. Following the immunizations, detailed evaluations of the immune responses to the vaccines are conducted over the next 8 weeks.]
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Documented HIV infection.
- •CD4+ cell count between 300 and 500 cells/mm
- •HIV-1 RNA < 500 by the branched-chain DNA assay (bDNA assay, Chiron) within 21 days of study entry [AS PER AMENDMENT 11/25/98:
- •Undetectable-plasma HIV titers (as defined by the FDA) by the branched-chain DNA test].
- •Established B cell lines [deleted AS PER AMENDMENT 11/25/98].
- •Response to at least one recall antigen in an in vitro assay of lymphocyte proliferative responses.
- •Life expectancy > 6 months [deleted AS PER AMENDMENT 11/25/98].
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Active opportunistic infection or HIV-related malignancy [HIV-related malignancy deleted AS PER AMENDMENT 11/25/98].
- •Peripheral neuropathy of grade 2 or higher by Division of AIDS toxicity criteria.
- •Concurrent Medication:
- •Other investigational HIV-drugs.
- •Immunomodulatory or potentially immunomodulatory drugs, such as glucocorticoids, hematopoietins, interleukin-2, interferon, or pentoxifylline.
- •Patients with the following prior conditions are excluded:
- •History of serious hypersensitivity to tetanus toxoid or any of the vaccine components.
- •Prior Medication:
- •Previous immunization with pneumococcal polysaccharide vaccine [or, AS PER AMENDMENT 11/25/98, keyhole limpet hemocyanin vaccine].
- •Tetanus toxoid booster within 5 years [deleted AS PER AMENDMENT 11/25/98].
- •Other investigational HIV-drugs within 6 weeks of enrollment.
- •Immunomodulatory or potentially immunomodulatory drugs, such as glucocorticoids, hematopoietins, interleukin-2, interferon, or pentoxifylline within 6 weeks of enrollment.
- •Risk Behavior:
- •Active drug or alcohol abuse.
- •Effective combination antiretroviral therapy including two nucleoside analog agents (ZDV, 3TC, ddI, ddC, or d4T) and nelfinavir or indinavir, for at least one month prior to study entry. [AS PER AMENDMENT 11/25/98:
- •On stable, effective, highly-active antiretroviral therapy with combinations of any FDA-approved anti-HIV drugs for at least 3 months prior to entry.]
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV InfectionsMycobacterium InfectionsTuberculosisHIV InfectionsNCT00004276National Center for Research Resources (NCRR)50
终止
2 期
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell LymphocytosisStage 0 Chronic Lymphocytic LeukemiaMonoclonal B-Cell LymphocytosisStage I Small Lymphocytic LymphomaStage I Chronic Lymphocytic LeukemiaNCT02309515Mayo Clinic12
已完成
2 期
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell DyscrasiasPlasma Cell DisorderNCT02041325Boston VA Research Institute, Inc.38
已完成
早期 1 期
Pneumonia Vaccine in Aging HIV Positive IndividualsPneumococcal InfectionNCT02558751University of Toledo Health Science Campus51
招募中
1 期
Plasmodium Immunotherapy for Lung CancerLung Cancer, Nonsmall CellNCT02786589State Key Laboratory of Respiratory Disease30